Comparative Pharmacology
Head-to-head clinical analysis: M ZOLE 3 COMBINATION PACK versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M ZOLE 3 COMBINATION PACK versus NYSTAFORM.
M-ZOLE 3 COMBINATION PACK vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Zinc pyrithione inhibits fungal growth by disrupting membrane transport and inhibiting energy metabolism.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
A single oral dose of 3 tablets (M-ZOLE 3 COMBINATION PACK) as a one-time treatment.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Terminal elimination half-life 20-30 hours in healthy adults; prolonged in renal impairment (up to 40-50 hours) and hepatic impairment
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Renal: ~70-80% as unchanged drug and metabolites; biliary/fecal: ~20%
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category C
Category C
Antifungal
Antifungal